UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 4, 2007 (April 2, 2007)
Alnylam Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
| Delaware
|
|
000-50743
|
|
77-0602661 |
| |
(State or Other Juris-
diction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 300 Third Street, Cambridge, MA
|
|
02142 |
| |
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (617) 551-8200
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| |
|
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| |
|
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| |
|
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
| |
|
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment
of Principal Officers; Compensatory Arrangements of Certain Officers.
(d)
On April 2, 2007, the Board of Directors (the "Board") of Alnylam Pharmaceuticals, Inc. (the “Company”)
elected Victor J. Dzau, M.D. as a Class III director with a term
expiring at the annual meeting of stockholders to be held in 2007.
Dr. Dzau was elected to fill a vacancy created by an increase in the
size of the board from eight to nine directors. Dr. Dzau will be compensated as a director pursuant to
the Company’s compensation policy for non-employee directors,
which is described in our Current Report on Form 8-K filed with the
Securities and Exchange Commission on September 18, 2006.